Home / Resources / Test Your Knowledge / March 11, 2017

March 11, 2017

Mar 11, 2017

When asked in a survey, 77% got it wrong! In head-to-head trials of dipeptidyl peptidase 4 (DPP-4) inhibitors vs glucagon-like peptide 1 (GLP-1) receptor agonists, GLP-1 receptor agonists showed more favorable outcomes in all of the following areas except which one?


Answer: B Greater tolerability


GLP-1 receptor agonists showed more favorable outcomes than DPP-4 inhibitors in terms of glycemic control, weight loss, beta-cell function, and reduction of postprandial triglycerides. However, DPP-4 inhibitors offered greater tolerability because GLP-1 receptor agonists were associated with a higher incidence of mild to moderate gastrointestinal adverse events.

Nauck M. Diabetes Obes Metab. 2016;18(3):203-216. Evidence in Practice: Using GLP-1 Receptor Agonists to Optimize Glycemic Control